Madrigal Pharmaceuticals (MDGL)
(Delayed Data from NSDQ)
$252.74 USD
+4.06 (1.63%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $253.00 +0.26 (0.10%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$252.74 USD
+4.06 (1.63%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $253.00 +0.26 (0.10%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Madrigal Pharmaceuticals (MDGL) Soars: Stock Adds 6.5% in Session
by Zacks Equity Research
Madrigal Pharmaceuticals (MDGL) was a big mover last session, as the company saw its shares rise more than 6% on the day.
Madrigal (MDGL) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Madrigal (MDGL) has no approved product in its portfolio. So, investors' complete focus on fourth-quarter earnings call will be revolving around the company's lead pipeline candidate, MGL-3196.
3 Buy-Ranked Biotech Stocks That Soared in 2017
by Benjamin Rains
The S&P 500 is up almost 20% in 2017, with the likes of technology giants Nvidia (NVDA) and Amazon (AMZN) helping lift the index to new heights.
What's in Store for Madrigal (MDGL) This Earnings Season?
by Zacks Equity Research
Madrigal (MDGL) expects data readout for its lead candidate MGL-3196 on its third-quarter earnings call.